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Background
Most recent antiphospholipid syndrome (APS) diagnostic criteria consider two main characteristics. On the one hand, the clinical manifestations and, on the other hand, the persistent positivity for at least one of the following antiphospholipid antibodies (APLAs): lupus anticoagulant (LAC), anticardiolipin antibodies (aCL), or anti-β2 glycoprotein I antibodies (aβ2GPI) [1] . Moreover, several studies regarding the diagnostic and prognostic impact of the so-called non-criteria APLAs were published [2, 3] , but their role in the APS pathogenesis remains unsettled [4] .
Systemic lupus erythematosus (SLE) is the most frequent autoimmune disease associated with APS and also, the pathogenesis of these two clinical conditions seems to be intricate [5] . There are, however, few studies concerning the role of non-criteria APLAs in SLE patients [6, 7] .
We analyzed here the relation between the history of deep vein thrombosis (DVT) in patients with APS associated with SLE with a large spectrum of antibodies (Abs), both criteria and non-criteria APLAs.
Methods
Cohort study
The study was conducted on patients fulfilling the 2012 SLICC SLE criteria [8] as well as the 2006 Sydney APS criteria [1] . Twenty-nine patients diagnosed with both APS and SLE, hospitalized in Colentina Clinical Hospital, Bucharest were consecutively enrolled. All patients signed an informed consent on inclusion. This study was approved by the Clinical Research Ethics Committee of the Carol Davila University of Medicine and Pharmacy Bucharest.
Variables
For all patients, the same clinical and biological data were registered in order not to alter the homogeneity of the group. Systemic Lupus Erythematosus Disease Activity Index (SLE-DAI) [9] score was assessed on recruitment in all cases.
The criteria and non-criteria APLAs profile searched for were as follows: IgG and IgM serotypes of anticardiolipin antibodies (aCL), anti-β2 glycoprotein I antibodies (aβ2GPI), antiphosphatidylserine antibodies (aPS), anti phosphatidylethanolamine antibodies (aPE), respectively antiprothrombin antibodies (aPT). All determinations were made by ELISA -Aesku Diagnostics, Wendelsheim, Germany using the analyzer Chemwell 2910, Awareness Technology, Palm City, Florida, USA. A cut-off of 18 UI/ ml was used in all tested for defining Abs positivity.
Statistical analysis
Categorical values are expressed as numbers and percentage and quantitative ones as mean ± standard deviation (SD) or median (minimum; maximum), med (min; max) according to their distribution. In bivariate analysis, the chi-square test was used to test differences for categorical variables, T-independent test for the normally distributed, while Mann-Whitney for the non-normally distributed variables. A p-value less than 0.05 was considered significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated when appropriate. Moreover, the area under curve (AUC) by ROC curve was used to evaluate the relation between APLAs titers and DVT presence. Multivariate analysis by logistic regression (stepwise-forward method, adjusted to the small sample) was tested. Also, univariate logistic regression with DVT as dependent variable and each APLAs as independent one was done. All analysis was performed by SPSS 16.0.
Results
Cohort study
Demographic, clinical, and laboratory characteristics are summarized in Table 1 . A total of 29 patients were included in the study, with net feminine predominance (96.6%). The mean age on inclusion was 45.2 years.
Venous thrombosis was present in the disease history of 10 patients (34.5%); for the rest, other clinical events, respectively arterial thrombosis or gestation pathology, sustained the APS diagnosis. There was no acute DVT event during the enrollment period of the patients included. Figure 1 presents the number of patients with the most important overlapping APS diagnostic clinical events recorded, namely DVT, arterial thrombosis, and obstetrical events. In 11 patients other APS events were noted, e.g. superficial vein thrombosis, venous thrombosis in other places than lower limbs (retinal, cava vein). The med (min; max) time from the DVT events occurrence to the inclusion in the study was 7 (0.5; 14) years.
LAC positivity, twice determinate, was the most frequent APS biological marker present in patients' history (96.6%). It was associated with the aCL positivity in 7 patients (24.1%).
For further analysis, the studied group was divided into two subgroups: patients with history of DVT (10 patients) and patients without medical history of DVT (19 patients).
DVT traditional risk factors
In regard to the traditional risk factors of thrombosis, no significant differences were found between the two subgroups analyzed: gen- Table 2 ).
Disease activity
The baseline SLEDAI score results were significantly higher in the subgroup of patients with DVT history: 7.0 (0.0 -22.0), respectively 2.0 (0.0 -12.0) points (Table 2 ). found significantly higher titers, when analyzed in absolute number, in the serum of patients with history of DVT (data presented in Table 3 ). In multivariate analysis, after introducing in turn each of the APLAs studied (positive/ negative), SLEDAI score, and also the inflammatory syndrome parameters, only the SLEDAI score remained significantly associated with the presence of DVT history (p < 0.05). When analyzing by the ROC curve, we found the best association for the IgG aPE titer, 0.879 (0.755-1.003). Also, in univariate logistic regression the IgG aPE presented the best association with DVT history, 2.383 (1.198-4.741), as presented in Table 4 . 
ALPAs relation with DVT events
Discussions
APLAs are some of the most encountered Abs in SLE patients, and their presence is related to thrombosis and recurrence of thrombosis [10] . Of these, LAC seems to carry the greater risk for either arterial or venous thrombotic event [11] .
Baseline LAC positivity appears to bring up a 42 % associated risk of DVT over a 20-year period [12] . Moreover, aβ2GPI was demonstrated to be associated with DVT in patients with APS associated with SLE [13] . The presence of IgG aCL in medium and high titer might also increases the risk of thrombosis [14] . Some of the non-criteria Abs, such as aPT may develop LAC activity and their presence might be related to APS clinical events [15] . Regarding the aPE significance in APS, we do not have enough data yet. In some research, their presence is not associated with clinical APS events [16] . There is also evidence of aPE association with venous thrombotic events [17] . aPE has also been described in a subgroup of patients with clinical APS features, but without serological positive criteria APLAs; patients classified as "seronegative" APS. In these cases, non-criteria APLAs, including aPE, could be identified [18] . The results of studies regarding APLAs expression and significance in APS are divergent and one reason might be the lack of standardization of the laboratory determinations; so, efforts have been made in recent years to reach accuracy in the APS diagnosis [19] .
In our analysis, we found significantly higher titers in the serums of patients with previous DVT for the criteria APLAs, IgG aCL and IgG aβ2GPI, but also for the non-criteria APLAs, IgG aPE and IgG aPT. After analysis by ROC curve, the IgG aPE showed the strongest association with the history of DVT.
Both disease activity and inflammatory syndrome are characterized by high variability over time in SLE patients. Moreover, DVT events are accompanied by inflammatory reactions. In our study, we did not identify higher levels of the inflammation parameters in patients with DVT history. On the contrary, patients with previous DVT presented higher disease activity on inclusion, as expressed by the SLEDAI score results. We can only emphasize that lupus patients with APS clinically expressed as DVT might represent a subgroup of patients with more severe underlying pathology.
In the present research a large number of criteria and non-criteria APLAs were tested in SLE patients with APS from a single center. There are, however, several limitations to this study. The most important is the low number of patients included, which did not allow the assessment of any regression model. Furthermore, there were no acute DVT events and so the changes of inflammation parameters or SLE disease activity cannot be attributed to thrombosis occurrence. Moreover, we present a cross-sectional study and therefore the DVT events were retrospectively registered.
In conclusion, the IgG aPE titer was the best correlated with the history of DVT, so we might presume that the non-criteria IgG aPE might be involved in DVT pathogenesis in patients with SLE and APS. SLE disease activity proved to be also correlated with the history of DVT.
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